
Rallybio Corp (RLYB) Stock Forecast & Price Target
Rallybio Corp (RLYB) Analyst Ratings
Bulls say
Rallybio Corp's Phase 1b proof-of-concept data for RLYB212 demonstrates a promising capability to swiftly eliminate transfused HPA-1a+ platelets, suggesting its potential as a preventative treatment for fetal and neonatal alloimmune thrombocytopenia (FNAIT), a condition currently lacking FDA-approved therapies. The initiation of dosing in the first pregnant woman at high risk for FNAIT marks a significant milestone, reflecting both the company's commitment to advancing innovative therapies and the considerable risk mothers are willing to take for potentially life-saving treatments for their unborn children. Additionally, the financial model indicates optimism regarding Rallybio's future placement in the market, highlighting a supportive outlook for development and approval pathways, particularly regarding RLYB116 for paroxysmal nocturnal hemoglobinuria (PNH).
Bears say
Rallybio Corp reported a net loss of $0.25 per share, indicating ongoing financial challenges as the company develops therapies for rare disorders. The company faces multiple risks, including potential delays in clinical trials and the possibility of unfavorable clinical data for key pipeline candidates, RLYB212 and RLYB116. Additionally, risks associated with partnerships and the prospect of long-term dilution contribute to a negative outlook for Rallybio's stock performance.
This aggregate rating is based on analysts' research of Rallybio Corp and is not a guaranteed prediction by Public.com or investment advice.
Rallybio Corp (RLYB) Analyst Forecast & Price Prediction
Start investing in Rallybio Corp (RLYB)
Order type
Buy in
Order amount
Est. shares
0 shares